| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
μ Opioid Receptor/MOR
|
|---|---|
| ln Vitro |
DAMGO (1–10 μM) does not down-regulate the expression of CXCR4 protein, but it dramatically diminishes the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival[2].
DAMGO (1 μM) efficiently suppresses the prostaglandin E 2 (PGE 2)-induced rise in a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R I Na). In other words, PGE 2 (1 μM) can raise the TTX-R I Na peak by 103% as opposed to 24.9% when DAMGO is added[3]. |
| ln Vivo |
DAMGO (i.v., 0.5-2 mg/kg) can effectively and durably reduce pain in injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner[4].
|
| Cell Assay |
For nine days in vitro, neurons are cultured in their original dish with DAMGO (10 μM) for twenty-four hours. The neurons are then moved to a dish with Mg2+-free saline containing glycine (15 μM) and exposed to either NMDA (100 μM) or CXCL12 (20 nM) in the absence of glia. Neurons are returned to the original glia-containing culture dishes following treatment. A 24-hour period is used to assess neural death. To distinguish between normal and apoptotic cells, use cleaved caspase-3 (1:100) staining in conjunction with Hoechst 33342 (3 μg/mL)[2].
|
| References |
|
| Additional Infomation |
(D-Ala(2)-mephe(4)-gly-ol(5))enkephalin is a peptide.
An enkephalin analog that selectively binds to the MU OPIOID RECEPTOR. It is used as a model for drug permeability experiments. |
| Molecular Formula |
C26H35N5O6
|
|---|---|
| Molecular Weight |
513.586
|
| Exact Mass |
513.259
|
| CAS # |
78123-71-4
|
| Related CAS # |
DAMGO TFA; 950492-85-0
|
| PubChem CID |
5462471
|
| Appearance |
White to off-white solid powder
|
| Density |
1.271g/cm3
|
| Boiling Point |
922.7ºC at 760 mmHg
|
| Flash Point |
511.8ºC
|
| Index of Refraction |
1.595
|
| LogP |
0.934
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
37
|
| Complexity |
752
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
|
| InChi Key |
HPZJMUBDEAMBFI-WTNAPCKOSA-N
|
| InChi Code |
InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1
|
| Chemical Name |
(2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
|
| Synonyms |
DAMGO
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (~194.7 mM)
DMSO: ~33.3 mg/mL (~64.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9471 mL | 9.7354 mL | 19.4708 mL | |
| 5 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL | |
| 10 mM | 0.1947 mL | 0.9735 mL | 1.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
